SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:uu-341933"
 

Search: onr:"swepub:oai:DiVA.org:uu-341933" > Expression of p53 p...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma

Ali, Abir Salwa (author)
Uppsala universitet,Onkologisk endokrinologi
Grönberg, Malin, 1980- (author)
Uppsala universitet,Onkologisk endokrinologi
Federspiel, Birgitte (author)
Rigshosp, Copenhagen Univ Hosp, Copenhagen, Denmark
show more...
Scoazec, Jean-Yves (author)
Inst Gustave Roussy, Villejuif, France
Hjortland, Geir Olav (author)
Univ Oslo, Oslo, Norway
Gronbaek, Henning (author)
Aarhus Univ Hosp, Aarhus, Denmark
Ladekarl, Morten (author)
Aarhus Univ Hosp, Aarhus, Denmark
Langer, Seppo W. (author)
Rigshosp, Copenhagen Univ Hosp, Copenhagen, Denmark
Welin, Staffan (author)
Uppsala universitet,Onkologisk endokrinologi
Vestermark, Lene Weber (author)
Odense Univ Hosp, Odense, Denmark
Arola, Johanna (author)
Univ Helsinki, Helsinki, Finland; Helsinki Univ Hosp, Helsinki, Finland
Osterlund, Pia (author)
Univ Helsinki, Helsinki, Finland; Helsinki Univ Hosp, Helsinki, Finland; Tampere Univ Hosp, Tampere, Finland
Knigge, Ulrich (author)
Univ Copenhagen, Rigshosp, Copenhagen, Denmark
Sorbye, Halfdan (author)
Haukeland Hosp, Bergen, Norway; Univ Bergen, Bergen, Norway
Grimelius, Lars (author)
Uppsala universitet,Experimentell och klinisk onkologi
Tiensuu Janson, Eva (author)
Uppsala universitet,Onkologisk endokrinologi,Uppsala Univ, Sect Endocrine Oncol, Dept Med Sci, Uppsala, Sweden.
show less...
 (creator_code:org_t)
2017-11-07
2017
English.
In: PLOS ONE. - : Public Library of Science (PLoS). - 1932-6203. ; 12:11
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Background Gastroenteropancreatic neuroendocrine carcinomas (GEP-NECs) are aggressive, rapidly proliferating tumors. Therapeutic response to current chemotherapy regimens is usually short lasting. The aim of this study was to examine the expression and potential clinical importance of immunoreactive p53 protein in GEP-NEC. Materials and methods Tumor tissues from 124 GEP-NEC patients with locally advanced or metastatic disease treated with platinum-based chemotherapy were collected from Nordic centers and clinical data were obtained from the Nordic NEC register. Tumor proliferation rate and differentiation were re-evaluated. All specimens were immunostained for p53 protein using a commercially available monoclonal antibody. Kaplan-Meier curves and cox regression analyses were used to assess progression-free survival (PFS) and overall survival (OS). Results All tumor tissues were immunoreactive for either one or both neuroendocrine biomarkers (chromogranin A and synaptophysin) and Ki67 index was >20% in all cases. p53 immunoreactivity was only shown in 39% of the cases and was not found to be a prognostic marker for the whole cohort. However, p53 immunoreactivity was correlated with shorter PFS in patients with colorectal tumors (HR = 2.1, p = 0.03) in a univariate analysis as well as to poorer PFS (HR = 2.6, p = 0.03) and OS (HR = 3.4, p = 0.02) in patients with colorectal tumors with distant metastases, a correlation which remained significant in the multivariate analyses. Conclusion In this cohort of GEP-NEC patients, p53 expression could not be correlated with clinical outcome. However, in patients with colorectal NECs, p53 expression was correlated with shorter PFS and OS. Further studies are needed to establish the role of immunoreactive p53 as a prognostic marker for GEP-NEC patients.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

  • PLOS ONE (Search for host publication in LIBRIS)

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view